-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Camidge said that many major advances in the treatment of non-small cell lung cancer have come from the molecular specific subgroups that define the disease, and researchers have been able to develop targeted treatments
"We are beginning to realize that non-small cell lung cancer is not a disease," Camidge said
Gene amplification is a driver of cancer
This new paper titled "Crizotinib in met-amplified NSCLC patients" was published in the June issue of the Journal of Thoracic Oncology and introduced a third method for defining NSCLC subgroups.
"Unlike gene mutations or gene rearrangements-either present or not-gene amplification is a constant variable," Camidge said
In this study, Camidge and other researchers focused specifically on MET amplification in a Pfizer-sponsored study
If MET expansion is a cancer driver in some patients, it makes sense that inhibiting MET can slow or stop the progression of NSCLC in these patients
To verify this theory, the study requires hospitals and cancer centers to use a genetic test called fluorescence in situ hybridization (FISH) to perform MET amplification on tumor samples from patients with non-small cell lung cancer
During the study period, a total of 88 patients with different levels of MET amplification received crizotinib
The results showed that patients with the highest level of MET amplification had the highest response rate to crizotinib treatment and experienced a longer survival period without tumor progression, while patients with lower levels of MET amplification had a poorer response to treatment
This study, which began in 2006, is one of the biggest efforts to determine relevant diagnostic tests for meaningful levels of MET gene amplification and to prove that MET inhibitor drugs are effective in treating NSCLC patients driven by MET amplification
Camidge said: "For this rare subtype of lung cancer, this is a long and difficult process, but I think this is quite good evidence that some patients just MET amplification caused their cancer
For seeing amplification testing and treatment
Camidge said there are many reasons why non-small cell lung cancer driven by MET expansion is unique
Second, it often occurs in lung cancer patients who are not usually identified as having carcinogenic factors, including smokers and the elderly
"This is not your classic driver oncogene subtype," he said
Because of this, Camidge said, patients with non-small cell lung cancer who have not been identified as driving oncogenes should consider MET amplification testing
Camidge said: "Although some sequencing tests can be compared with FISH tests and reliably detect gene amplification, others cannot
When using inhibitors to treat patients with amplification-driven NSCLC, Camidge said that pharmaceutical companies began to explore satisfaction amplification as additional new and existing target satisfaction inhibitors, and he hopes that the team’s findings will help inform R&D and ultimately help patients.
.
"This is a truly operable oncogene," he said
.
"It's rare, but it's true
.
"
Journal Reference :
D.
Ross Camidge et al.
Crizotinib in Patients With MET-Amplified NSCLC .
Journal of Thoracic Oncology , 2021 DOI: 10.
1016/j.
jtho.
2021.
02.
010